Conference Reports for NATAP

Back

14th European AIDS Conference Oct 16-19 2013 Brussels, Belgium     Low HDL Cholesterol Is Main Lipid Abnormality in HIV+/HIV- Comparison in HIV UPBEAT Study - (12/06/13)   Treatment of Chronic Hepatitis C: The Revolution! - (10/29/13)   Differing Effects of Low- and High-Fat Meals on New Raltegravir Formulation - Written by Mark Mascolini - (10/28/13)   PI Use, Female Gender, HCV, Detectable Sub-50 Viral load Predict Rebound From Under 50 Copies in Italian Group - Written by Mark Mascolini - (10/28/13)   One Percent in Stribild and Cobicistat Trials Pick Up HCV--Treatment Response Good - Written by Mark Mascolini - (10/28/13)   Lean Mass Inches Out Fat Mass as Predictor of Low Bone Density With HIV, HIV UPBEAT Cohort - Written by Mark Mascolini - (10/25/13)   Merck Presents New Pharmacokinetic Data on ISENTRESS® (raltegravir) at 14th European AIDS Conference - (10/25/13)   Bone Loss Worse in HIV+ vs HIV-Neg, Lower Body Weight Predicts Bone Loss in MSM: "Prevalence and determinants of reduced bone mineral density in aging HIV-1-positive and HIV-negative individuals" in AGEhIV Cohort Amsterdam - (10/25/13)   Neither HIV Nor Tenofovir Tied to Low Bone Density in Large Amsterdam Study (AGEhIV Cohort) - (10/25/13)   Lean Mass Inches Out Fat Mass as Predictor of Low Bone Density With HIV - (10/25/13)   EACS: CHANGES IN BONE TURNOVER MARKERS AND ASSOCIATION WITH DECREASED TOTAL BONE MINERAL DENSITY IN TREATMENT-NAIVE SUBJECTS TAKING LOPINAVIR/RITONAVIR (LPV/r) COMBINED WITH RALTEGRAVIR (RAL) OR TENOFOVIR/EMTRICITABINE (TDF/FTC) - (10/23/13)   Classic Risk Factors, But Not HIV, Linked to Arterial Stiffness in Middle-Aged - Written by Mark Mascolini - (10/23/13)   Bone Turnover Marker Changes Early in ART Predict Bone Loss After 96 Weeks - Written by Mark Mascolini - (10/23/13)   Statin Use Cuts All-Cause Mortality 75% in Spanish HIV Cohort - Written by Mark Mascolini - (10/23/13)   Meta-Analysis of Dolutegravir vs Guideline-Recommended Agents for Naive - Written by Mark Mascolini - (10/23/13)   Once-Daily ART v Twice-Daily/Pill Burden Meta-Analysis Evaluates Adherence/Viral Control - Written by Mark Mascolini - (10/23/13)   48 weeks outcomes of atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: interim analysis results of the MODAt Study - (10/23/13)   Osteoporosis Triples Risk of Later Fracture in 1000-Person US HIV Group - Written by Mark Mascolini - (10/21/13)   Twice-Higher Latest Vitamin D Almost Halves Odds of Death in EuroSIDA - Written by Mark Mascolini - (10/21/13)   Once-Daily Raltegravir for 48 Weeks as Maintenance Therapy in Paris - Written by Mark Mascolini - (10/21/13)   'Acute HCV BUT No HBV Reported' - Reports of Viral Hepatitis B and C in HIV Patients Participating in Clinical Trials of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF and Cobicistat-boosted Atazanavir plus Emtricitabine/Tenofovir DF - (10/21/13)   Safety and Tolerability of Switching from Twice Daily Raltegravir plus Truvada to STRIBILD in Virologically Suppressed, HIV-1 Infected Subjects - (10/21/13)   STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Maintains Non-Inferiority to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults Week 96 Results - (10/21/13)   Dual therapy with lopinavir/ritonavir (LPV/r) and lamivudine (3TC) is non-inferior to standard triple drug therapy in naive HIV-1 infected subjects: 48-week results of the GARDEL study - (10/21/13)   Retrospective Comparison of Etravirine and Darunavir/Ritonavir as Dual Therapy in Early Treatment-Experienced Subjects (INROADS) to a Matched Historical Control Cohort - (10/21/13)   Virological Efficacy, Durability and Safety of Darunavir/r plus Etravirine (DRV/r-ETV) Dual Regimen in ART-Experienced Patients - (10/21/13)   Simplification to dual therapy containing raltegravir and darunavir/ritonavir in HIV-infected patients on virologically suppressive therapy including nucleoside/nucleotide analogues and ritonavir-boosted boosted protease inhibitors - (10/21/13)   Substantial rates of Acute Hepatitis C Reinfection in European HIV-positive Patients - (10/21/13)   STARTVerso 4 Phase iii trial of faldaprevir once-daily plus peg interferon α -2a and ribavirin (PR) in patients with HiV and HCV genotype-1 co-infection - (10/20/13)   Simeprevir (TMC435) in combination with peginterferon/ribavirin in patients co-infected with HCV genotype-1 and HIV-1: Primary analysis of the C212 study - (10/20/13)   Simeprevir with peginterferon/ribavirin in treatment-naïve or experienced patients with chronic HCV genotype 4 infection: Interim results of a Phase III trial - (10/20/13)   Summary of pharmacokinetic drug-drug interactions for simeprevir (TMC435), a hepatitis C virus Ns3/4A protease inhibitor - (10/20/13)   Low Bone Mineral Density is Associated with Increased Risk of Incident Fracture in HIV-infected Adults - (10/20/13)   Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons: results from the EuroSIDA cohort study - (10/18/13)   Final Week 48 Analysis of Cenicriviroc (CVC) Compared to Efavirenz (EFV), in Combination with Emtricitabine/Tenofovir (FTC/TDF), in Treatment-Naïve HIV-1-Infected Adults with CCR5-Tropic Virus (Study 652-2-202; NCT01338883) - (10/18/13)   Week 96 Renal Safety Update of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF from Two Phase 3 Randomized Controlled Trials - (10/18/13)   Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) Has Durable Efficacy and Differentiated Safety Compared to Atazanavir Boosted by Ritonavir Plus Emtricitabine/Tenofovir DF in Treatment-naïve HIV-1 Infected Patients: Week 144 Results - (10/18/13)   Once-Daily Oral GSK1265744 (744) as Part of Combination Therapy in Antiretroviral-Naive Adults: 24-Week Safety and Efficacy Results From the LATTE Study (LAI116482) - (10/18/13)   A Single Dose Food Effect Study of Raltegravir (RAL) Formulations Once Daily Tablet - (10/17/13)   Once-Daily Dolutegravir Versus Darunavir/Ritonavir in Antiretroviral Naïve Adults: 48 Week Subgroup Analyses from FLAMINGO - (10/17/13)   48-Week Efficacy of Dolutegravir Relative to Commonly Used 3rd Agents in Treatment-Naive HIV-1-Infected Patients: A Systematic Review and Network Meta-analysis - (10/16/13)   Bristol-Myers Squibb Launches Initiative to support search for a cure in chronic viral diseases (HIV/HBV/HCV) - (10/16/13)   Activity of Dolutegravir (DTG) 50 mg BID vs Placebo (PBO) Over 7 Days of Functional Monotherapy in Patients Harbouring Raltegravir- and/or Elvitegravir-Resistant Virus: Primary Endpoint Results of the VIKING-4 Study (ING116529) - (10/16/13)